Numerous additional in vitro studies for both melanoma and other cancer cells have shown that the Mcl-1/Noxa ratio is critical for determining resistance or sensitivity to ABT-737 [13], [14], [15], [16], [17], [18]. Here, MCL1 is linked to melanoma.